ARS Pharmaceuticals, Inc.
SPRY
$9.82
$0.272.83%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -51.15M | -44.88M | -33.94M | 49.93M | -19.13M |
| Total Depreciation and Amortization | 391.00K | 279.00K | 280.00K | 29.00K | 21.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.78M | 6.06M | 3.34M | 2.72M | 1.77M |
| Change in Net Operating Assets | -1.07M | -1.05M | -10.42M | -10.68M | 2.88M |
| Cash from Operations | -47.05M | -39.59M | -40.74M | 42.00M | -14.47M |
| Capital Expenditure | -197.00K | -51.00K | -91.00K | -302.00K | -140.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -44.78M | 48.62M | 29.16M | -101.46M | 16.96M |
| Cash from Investing | -44.98M | 48.57M | 29.06M | -101.76M | 16.82M |
| Total Debt Issued | 97.75M | -- | -- | 69.38M | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 479.00K | 2.70M | 725.00K | 1.53M | 680.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 1.82M | -- | -- | -- | -- |
| Cash from Financing | 100.05M | 2.70M | 725.00K | 70.92M | 680.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 8.02M | 11.68M | -10.95M | 11.16M | 3.03M |